IP Verse

Prostaglandin Conjugates And Derivatives For Treating Glaucoma And Ocular Hypertension - EP3206693

The patent EP3206693 was granted to Alcon on Aug 3, 2022. The application was originally filed on Oct 15, 2015 under application number EP15791399A. The patent is currently recorded with a legal status of "Revoked".

EP3206693

ALCON
Application Number
EP15791399A
Filing Date
Oct 15, 2015
Status
Revoked
Aug 2, 2024
Grant Date
Aug 3, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STADA ARZNEIMITTELApr 27, 2023HAMM & WITTKOPPADMISSIBLE

Patent Citations (2) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
EXAMINATIONWO9002124
INTERNATIONAL-SEARCH-REPORTWO2013163219

Non-Patent Literature (NPL) Citations (6) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- JAY L. KATZ ET AL, "Latanoprostene Bunod 0.024% Significantly Reduces and Maintains Mean Diurnal Intra-Ocular Pressure (IOP) Compared to Latanoprost 0.005% in Subjects with Open Angle Glaucoma or Ocular Hypertension", IOVS ARVO ANNUAL MEETING ABSTRACT, (20130601), vol. 54, page 460, XP055466142
EXAMINATION- E. HAMPTON SESSIONS ET AL, "Benzimidazole- and benzoxazole-based inhibitors of Rho kinase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (20081201), vol. 18, no. 24, doi:10.1016/j.bmcl.2008.10.095, ISSN 0960-894X, pages 6390 - 6393, XP055158495
EXAMINATION- NELLO MAINOLFI ET AL, "An Effective Prodrug Strategy to Selectively Enhance Ocular Exposure of a Cannabinoid Receptor (CB 1/2 ) Agonist", JOURNAL OF MEDICINAL CHEMISTRY, (20130711), vol. 56, no. 13, doi:10.1021/jm4004939, ISSN 0022-2623, pages 5464 - 5472, XP055465970
EXAMINATION- SHARIF N A ET AL, "AL-34662: A Potent, Selective, And Efficacious Ocular Hypotensive Serotonin-2 Receptor Agonist", JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUT, MARY ANN LIEBERT, INC., NEW YORK, NY, US, (20070101), vol. 23, no. 1, doi:10.1089/JOP.2006.0093, ISSN 1080-7683, pages 1 - 13, XP008109787
EXAMINATION- MEGAN E. CAVET ET AL, "Nitric Oxide (NO): An Emerging Target for the Treatment of Glaucoma", INVESTIGATIVE OPTHALMOLOGY & VISUAL SCIENCE, US, (20140814), vol. 55, no. 8, doi:10.1167/iovs.14-14515, ISSN 1552-5783, page 5005, XP055465991
EXAMINATION- LARRY KEEFER, "Nitric Oxide (NO)- and Nitroxyl (HNO)-Generating Diazeniumdiolates (NONOates): Emerging Commercial Opportunities", CURRENT TOPICS IN MEDICINAL CHEMISTRY, NL, (20050701), vol. 5, no. 7, doi:10.2174/1568026054679380, ISSN 1568-0266, pages 625 - 636, XP055466405

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents